INTRODUCTION {#S1}
============

T cell activation is a hallmark of chronic HIV infection ([@R38]; [@R60]). T cells from HIV^+^ patients express increased levels of activation markers, CD38 and HLA-DR, which predict more rapid progression to AIDS in advanced HIV infection ([@R3]; [@R28]; [@R39]; [@R42]). Even with effective anti-retroviral therapy, T cell activation remains elevated in HIV- infected individuals, likely as a result of viral persistence ([@R38]; [@R46]). Lymphoid tissues are a major reservoir of HIV infection ([@R37]; [@R41]). Viral infection leads to disrupted lymphoid architectures and altered cellular differentiation ([@R36]). In particular, studies of human primary lymph nodes (LNs) from untreated HIV patients have revealed an expansion of follicular helper T (T~FH~) cells ([@R44]; [@R52]), which are classically identified by the expression of CXCR5, a chemokine receptor that enables proper follicular localization in the LN ([@R17]; [@R33]). T~FH~ cells are necessary for the development of affinity-matured broadly neutralizing antibody-producing B cells ([@R32]). However, despite an increase in the abundance of T~FH~ cells in the LN, protective antibody responses to vaccines are generally diminished in the setting of HIV infection ([@R18]; [@R23]). T~FH~ cells from HIV^+^ patients acquire a skewed functional phenotype and limited T cell receptor (TCR) diversity under persistent antigen stimulation ([@R69]). Functional assays performed *in vitro* also showed T~FH~ cells from HIV-infected LNs were less effective at providing help to B cells ([@R19]).

Due to the importance of T~FH~ cells in generating protective antibody responses, there have been substantial efforts to understand and manipulate T~FH~ cells for better vaccine efficacy. By comparison, much less is known about other cell types in inflamed LNs. Because HIV-driven immune hyperactivation broadly impact T cells in lymphoid tissues ([@R9]), we hypothesized that a more comprehensive understanding of the complexity of activated T cells in the lymphoid compartment could provide insights into dysregulated T:B cell interactions. Unique functional and phenotypic states identified in this setting may be harnessed for the improvement of efficacious protective antibody responses. In this study, we combined a number of high-dimensional and functional approaches to examine activated T cells in primary human LNs from HIV-infected individuals, with the goal of discovering T cell populations that contribute to abnormal responses in the lymphoid environment during chronic viral infection.

RESULTS {#S2}
=======

High-Dimensional Phenotypic Analyses Revealed an Accumulation of Activated CXCR5^−^ CD4^+^ T Cells in HIV-Infected LNs {#S3}
----------------------------------------------------------------------------------------------------------------------

T cell activation in chronic HIV infection predicts increased mortality in severe disease ([@R29]). To better understand the heterogeneity of activated T cells in the LN, we performed mass cytometry with a 36-marker panel using LNs from eight virally active HIV^+^ patients. Cryopreserved LN cells were stimulated with phorbol-12-myristate-13-acetate (PMA) and ionomycin in the presence of brefeldin A and monensin for 5 h, stained with metal-conjugated antibodies, and analyzed on the mass cytometer, cytometry by time of flight 2 (CyTOF2). Data normalization was performed using a bead-based standards to minimize variations due to batch and machine performance ([@R27]). We defined activated T cells by CD38 and HLA-DR expression and compared double-positive T cells to quiescent CD38^−^HLA-DR^−^ CD3^+^T cells ([Figure 1A](#F1){ref-type="fig"}). Activated or quiescent CD3^+^ T cells were further divided into CD4^+^ αβ, CD8^+^ αβ, or γδ T cells. The majority of CD3^+^ cells expressed αβ TCRs, mostly CD4^+^ in the CD38^−^HLA-DR^−^ subset but predominantly CD8^+^ in the CD38^+^HLA-DR^+^ subset ([Figure 1A](#F1){ref-type="fig"}). Activated T cells were enriched in memory and effector molecules, whereas markers indicative of a less differentiated state, TCF1 and CCR7, were more highly expressed in quiescent T cells ([Figure 1B](#F1){ref-type="fig"}). Although activated T cells contained a lower relative frequency of CD4^+^ T cells, CD38^+^HLA-DR^+^ CD4^+^ T cells were more abundant in patients with more severe HIV infection ([Figure S1A](#SD1){ref-type="supplementary-material"}).

To further examine CD4^+^ T cells for activation-associated changes relevant to HIV infection, equal numbers of manually gated CD4^+^ T cells from each donor were combined, and nonlinear dimensional reduction was performed using Uniform Manifold Approximation and Projection (UMAP; [Figures S1B](#SD1){ref-type="supplementary-material"}--[S1C](#SD1){ref-type="supplementary-material"}) ([@R6]). We observed a substantial population of Foxp3^+^ cells and heterogeneous interferon gamma (IFN-γ), interleukin-2 (IL-2), and tumor necrosis factor alpha (TNF-α) expression, but few cells with positive IL-4, IL-13, or IL-17 staining ([Figure S1C](#SD1){ref-type="supplementary-material"}). While CXCR5 and PD-1 co-expression classically defines T~FH~ cells, PD-1 staining covered a broader region on UMAP and included areas with little CXCR5 signal ([Figure 1C](#F1){ref-type="fig"}). PD-1^+^ cells with weak or absent CXCR5 expression were concentrated in areas with higher CD38, ICOS, and Ki67 staining ([Figure S1C](#SD1){ref-type="supplementary-material"}). To better delineate cellular heterogeneity with respect to PD-1 and CXCR5, we subdivided CXCR5^+^ and CXCR5^−^ cells by high (++), intermediate (+), or negative (−) PD-1 expression ([Figure S1D](#SD1){ref-type="supplementary-material"}). The mean intensity of individual markers expressed by each subset was grouped in a heatmap by hierarchical clustering. This separated CD4^+^ T cells by the level of PD-1 expression, with PD-1^++^ cells staining most strongly for other markers of T cell activation, including CD38, Ki67, CD71, ICOS, and HLA-DR ([Figures 1D](#F1){ref-type="fig"} and [1E](#F1){ref-type="fig"}). To validate the findings above, we performed fluorescent cytometry on a separate set of LN cells from HIV^+^ patients and healthy controls (HCs) and subdivided CD4^+^ T cells as in the CyTOF dataset ([Figure 1F](#F1){ref-type="fig"}). Compared to HCs, CD4^+^ T cells expressing intermediate or high levels of PD-1 were significantly elevated in HIV-infected LNs ([Figure 1G](#F1){ref-type="fig"}). CXCR5^−^PD-1^++^ lymphocytes contained a high frequency of CD38^+^ T cells, which was further increased in the ICOS^+^ subset (ICOS^−^: 31.5%, ICOS^+^: 68.2%, [Figure 1I](#F1){ref-type="fig"}). Our data were consistent with prior work by [@R52], which also demonstrated an expansion of activated CXCR5^−^PD-1^+^ T cells in HIV-infected LNs. However, the significance of this population within the context of HIV infection remains unclear. Using a previously acquired CyTOF dataset from a larger set of HIV-infected LN samples ([@R69]), we showed that CXCR5^−^ memory CD4^+^ T cells with double PD-1 and ICOS expression were associated with more severe HIV infection by low blood CD4:CD8 ratio and CD4^+^ T cell count ([Figures 1J](#F1){ref-type="fig"} and [S2A](#SD1){ref-type="supplementary-material"}--[S2D](#SD1){ref-type="supplementary-material"}). Identification of activated PD-1-expressing CXCR5^−^ T cells by positive CD38 staining revealed similar associations ([Figures S2E](#SD1){ref-type="supplementary-material"}--[S2G](#SD1){ref-type="supplementary-material"}). Taken together, our data provided a broad overview of T cells in HIV-infected LNs and revealed pathologic accumulation of activated CXCR5^−^ CD4^+^ T cell population with high levels of PD-1 expression during chronic HIV infection.

CXCR5^−^PD-1^+^ CD4^+^ T Cells Express Co-inhibitory Receptors but Retain Cytokine-Producing Potential {#S4}
------------------------------------------------------------------------------------------------------

PD-1 is a co-inhibitory receptor expressed by T~FH~ cells and up-regulated by exhausted T cells. Thus, we initially hypothesized that PD-1 expression on CXCR5^−^ T cells marked a population of exhausted CD4^+^ T cells driven by the depleted CD4^+^ T cell niche and chronic antigen stimulation by HIV infection. To test this, we stained HIV-infected LN cells for additional co-inhibitory receptors, Lag-3, TIGIT, 2B4, Tim-3, and CD39 ([@R16]; [@R63]). This showed an increased expression of 2B4, Lag-3, and TIGIT on PD-1-expressing T cells, irrespective of CXCR5 expression. In addition, CXCR5^−^PD-1^++^ T cells also expressed a higher level of Tim-3 and CD39 compared to the PD-1 negative subsets ([Figures 2A](#F2){ref-type="fig"} and S3A). To examine differences in functional potential, we first broadly divided cells into PD-1^−^ or PD-1^+/++^ subsets. This showed TNF-α and/or IFN-γ production by PD-1-expressing T cells following PMA and ionomycin stimulation ([Figure 2B](#F2){ref-type="fig"}). To refine this analysis, Boolean gates for IL-2, IFN-γ, and TNF-α were applied onto individual CD4^+^ subsets to identify all combinations of cytokine production ([Figure S3B](#SD1){ref-type="supplementary-material"}). Compared to the CXCR5^−^PD-1^−^ subset, CXCR5^−^PD-1^++^ T cells contained a significantly higher frequency of IFN-γ-producing cells, including single IFN-γ-secreting cells (4.26%); double IFN-γ and TNF-α producers (17.04%); and triple IFN-γ+TNF-α-+IL-2-producing T cells (7.23%, [Figures 2C](#F2){ref-type="fig"} and [S3C](#SD1){ref-type="supplementary-material"}). To determine if CXCR5^−^PD-1^++^ T cells can also produce IL-21, a critical mediator of B cell selection and differentiation in the LN, we analyzed a previously acquired CyTOF dataset on HIV-infected LNs that included IL-21 staining ([@R69]). This identified IL-21 production in a substantial fraction of memory CD4^+^ T cells with CXCR5^−^PD-1^2++^ phenotype (CXCR5^−^PD-1^−^: 2.90%, CXCR5^−^PD-1^++^: 12.09%, CXCR5^+^PD-1^++^: 8.92%, [Figures 2D](#F2){ref-type="fig"} and [S4A](#SD1){ref-type="supplementary-material"}). Staining by flow cytometry also showed IL-21 secretion was not restricted to CXCR5^+^ T cells ([Figures S4B](#SD1){ref-type="supplementary-material"} and [S4C](#SD1){ref-type="supplementary-material"}). Collectively, these data demonstrated preservation of cytokine-producing potential in a subset of CXCR5^−^ CD4^+^ T cells that displayed increased co-inhibitory receptor expression.

CXCR5^−^PD-1^+^ICOS^+^ T Cells Express T~FH~-Associated Proteins and Function {#S5}
-----------------------------------------------------------------------------

The ability to produce IL-21 under stimulation suggested the possibility that the CXCR5^−^ population may be more similar to T~FH~ cells than exhausted T cells or other types of conventional CD4^+^ T cells. To evaluate additional T~FH~-cell-related protein expression, we examined CXCR5^−^ T cells for upregulation of BCL6, Maf, and CD84. BCL6 and Maf are key transcriptional regulators of T~FH~ cell specification and function ([@R5]; [@R70]), whereas CD84 belongs to signaling lymphocyte activation molecule (SLAM) family of receptors that transduces adhesion signals to drive germinal center differentiation ([@R12]). Herein, we included ICOS and CD45RO to more precisely define T~FH~ cells ([Figure S5A](#SD1){ref-type="supplementary-material"}). We also added ICOS to the selection of PD-1-expressing CXCR5^−^ T cells because it enriched for the activation phenotype and identified a subset of CXCR5^−^ T cells that correlated with more severe HIV infection ([Figures 1I](#F1){ref-type="fig"} and [1J](#F1){ref-type="fig"}). PD-1^+^ICOS^+^ memory cells were compared to PD-1^−^ICOS^−^ memory cells and naive CD4^+^ T cells. Analyses of BCL6, Maf, and CD84 staining in CXCR5^−^PD-1^+^ICOS^+^ T cells showed higher expression for all three proteins relative to non-T~FH~ cells but a weaker staining for BCL6 and Maf compared to T~FH~ cells ([Figures 3A](#F3){ref-type="fig"} and [S4D](#SD1){ref-type="supplementary-material"}).

To determine if the partial resemblance between CXCR5^−^PD-1^+^ICOS^+^ T cells and T~FH~ cells extended to a similar functional program, we performed T:B coculture assays to assess the potential for B cell helper function. Naive, CXCR5^−^PD-1^−^ICOS^−^, CXCR5^−^PD-1^+^ICOS^+^, and T~FH~ cells were sorted and cultured with autologous B cells at 1:1 ratio and stimulated with Staphylococcal Enterotoxin B (SEB). CXCR5^−^PD-1^+^ICOS^+^ T cells drove plasma cell differentiation and immunoglobulin G (IgG) production similar to the level observed in T~FH~ cells ([Figures 3B](#F3){ref-type="fig"}--[3D](#F3){ref-type="fig"}). Interestingly, B cells cocultured with CXCR5^−^PD-1^−^ICOS^−^ memory T cells also produced significantly more antibodies compared to naive T cells, at a level comparable to or exceeding that of B cells cocultured with T~FH~ cells in one-third of the samples (5/15). This observation may be a nonspecific feature of the experimental condition or could reflect a broader range of B cell helper activity by other types CD4^+^ T cells. The ability of CXCR5^−^PD-1^−^ICOS^−^ T cells to survive and expand better *in vitro* likely also contributed to this finding ([Figure 3E](#F3){ref-type="fig"}).

Next, we examined the *in vivo* relevance of CXCR5^−^PD-1^+^ICOS^+^ T cells by measuring correlative changes in B cell differentiation in primary LN samples. In the context of Toll-like receptor (TLR) engagement, IFN-γ has been shown to induce a distinct effector B cell subset characterized by T-bet expression ([@R4]; [@R40]; [@R57]). Because CXCR5^−^PD-1^++^ T cells exhibited an IFN-γ-dominant functional profile ([Figure 2C](#F2){ref-type="fig"}) and produced a higher level of IFN-γ in the supernatant compared to T~FH~ cells ([Figure 3F](#F3){ref-type="fig"}), we hypothesized that IFN-γ-producing CXCR5^−^PD-1^+^ICOS^+^ T cells could promote B cell differentiation toward the T-bet^+^ subset. Using T-bet and CXCR3 co-expression to identify T-bet^+^ B cells, we showed higher T-bet^+^ B cell frequency in HIV-infected LNs compared to cells from HCs, which positively correlated with the frequency of IFN-γ-producing CXCR5^−^PD-1^+^ICOS^+^ T cells ([Figures 3G](#F3){ref-type="fig"} and [3H](#F3){ref-type="fig"}). Collectively, the *in vitro* functionality of CXCR5^−^PD-1^+^ICOS^+^ T cells and the associated B cell changes in primary LNs provide supportive evidence for regulation of B cell responses by CXCR5^−^PD-1^+^ICOS^+^ T cells during chronic HIV infection.

CXCR5^−^PD-1^+^ICOS^+^ Subset Contains HIV-Specific T Cells that Drive B Cell Responses *In Vitro* {#S6}
--------------------------------------------------------------------------------------------------

Past studies have found an expansion of HIV-specific T~FH~ cells during chronic HIV infection ([@R44]; [@R52]; [@R69]). Given the functional and phenotypic similarity between CXCR5^−^PD-1^+^ICOS^+^ T cells and T~FH~ cells, next we determined if the CXCR5^−^PD-1^+^ICOS^+^ subset was also enriched for HIV-specific T cells. We stimulated total LN cells with overlapping pools of Gag peptides for 18 h and identified peptide-specific T cells within naive, CXCR5^−^PD-1^−^ICOS^−^, CXCR5^−^PD-1^+^ICOS^+^, or T~FH~ cells by CD25 and OX40 upregulation ([@R21]). The frequency of CD25 and OX40 double-positive T cells in DMSO-vehicle-treated backgrounds were subtracted from Gag peptide stimulated cultures to calculate the frequency of Gag-reactive T cells. On average, 1.86% of CXCR5^−^PD-1^+^ICOS^+^ (0%--4.2%) and 0.83% of T~FH~ cells (0%--3.20%) expressed OX40 and CD25 in response to peptide stimulation, whereas negligible numbers of CD25^+^OX40^+^ cells were detected in the naive and CXCR5^−^PD-1^−^ICOS^−^ subsets ([Figures 4A](#F4){ref-type="fig"} and [4B](#F4){ref-type="fig"}).

To examine the functional activity of HIV-specific T cells within the naive, CXCR5^−^PD-1^−^ICOS^−^, CXCR5^−^PD-1^+^ICOS^+^, or T~FH~ cell fraction, sort purified T cell subsets were cultured with B cells and stimulated by Gag and Env peptides. B cell response was absent in naive and CXCR5^−^PD-1^−^ICOS^−^ T cell cocultures. In contrast, sufficient numbers of CXCR5^−^PD-1^+^ICOS^+^ and T~FH~ cells responded to HIV peptides to drive plasma cell differentiation and IgG production by B cells, despite a lower overall survival of these cells in culture ([Figures 4C](#F4){ref-type="fig"}--[4E](#F4){ref-type="fig"}; [Figure S6A](#SD1){ref-type="supplementary-material"}). Analyses of antibody specificity showed limited recognition of recombinant Gag/Env proteins and no binding to Gag/Env peptides. HIV-specific antibodies accounted for 4% (0%--10%) of total IgG antibodies in the supernatant from T~FH~ cell cocultures and 10% (0%--49%) of the antibodies generated in the presence of CXCR5^−^PD-1^+^ICOS^+^ T cells ([Figures 4F](#F4){ref-type="fig"} and [4G](#F4){ref-type="fig"}). Consistent with this, HIV peptide-stimulated CXCR5^−^PD-1^+^ICOS^+^ T cells induced antibody secreting cells (ASCs) by enzyme-linked immune absorbent spot assay (ELISPOT), which contained rare, but appreciable, B cell responses against Gag/Env proteins ([Figures S6B](#SD1){ref-type="supplementary-material"}--[S6D](#SD1){ref-type="supplementary-material"}). Collectively, these data identified HIV-specific T cells within the CXCR5^−^PD-1^+^ICOS^+^ phenotypic subset and provide evidence for their ability to promote B cell response *in vitro*.

CXCR5^−^PD-1^+^ICOS^+^ T Cells Are Clonally Related to T~FH~ Cells and Share a Similar Epigenetic Landscape {#S7}
-----------------------------------------------------------------------------------------------------------

The enrichment of T cells reactive to the same antigens suggested the possibility that CXCR5^−^PD-1^+^ICOS^+^ cells and T~FH~ cells shared overlapping TCR repertoires. We tracked the clonal relationship between CXCR5^−^PD-1^+^ICOS^+^ T cells and T~FH~ cells by taking advantage of TCR sequence as a unique T cell identifier. T cells expressing the identical TCR sequences are necessarily generated from the same precursors, and thus we can use TCR sequences to infer the relatedness between phenotypically distinct populations. We performed TCR repertoire sequencing on sorted naive, CXCR5^−^PD-1^−^ICOS^−^, CXCR5^−^PD-1^+^ICOS^+^, and T~FH~ cells ([Figure S5A](#SD1){ref-type="supplementary-material"}). Common sequences shared between CXCR5^−^PD-1^+^ICOS^+^ and other T cell subsets were shown as connecting lines on circos plots and quantified by the Bhattacharyya Coefficient as an index of sequence similarity ([@R8]) ([Figure 5A](#F5){ref-type="fig"}). Analysis of the combined TCR sequencing data from 9 donors showed that the clonal overlap between CXCR5^−^PD-1^+^ICOS^+^ T cells and other T cell subsets was highest with T~FH~ cells, which significantly exceeded the repertoire similarities with naive cells or CXCR5^−^PD-1^−^ICOS^−^ T cells ([Figure 5B](#F5){ref-type="fig"}).

The overlap in TCR sequence repertoire between CXCR5^−^PD-1^+^ICOS^+^ and T~FH~ cells could reflect variable CXCR5 expression between cells along a single differentiation trajectory and/or divergent differentiation from a shared CXCR5^−^ precursor population. To distinguish between these possibilities, transposase-accessible chromatin with sequencing (ATAC-seq) was performed to provide a glimpse into the differentiation history of CXCR5^−^PD-1^+^ICOS^+^ T cells. We anticipated CXCR5^−^PD-1^+^ICOS^+^ T cells to have open chromatin region around CXCR5 promoter region if these cells had previously expressed CXCR5 and remained transcriptionally permissive for CXCR5 expression. Alternatively, we would expect to find a closed CXCR5 promoter region if CXCR5^−^PD-1^+^ICOS^+^ T cells did not go through a CXCR5^+^ state or if changes in the chromatin structure were short-lived. We generated a chromatin accessibility map for naive, CXCR5^−^PD-1^−^ICOS^−^, CXCR5^−^PD-1^+^ICOS^+^, and T~FH~ cells. Principal-component analysis (PCA) separated naive and CXCR5^−^PD-1^−^ICOS^−^ T cells from CXCR5^−^PD-1^+^ICOS^+^ T cells along the first and second principal components (PCs) ([Figure 5C](#F5){ref-type="fig"}). Notably, CXCR5^−^PD-1^+^ICOS^+^ cells and T~FH~ cells occupied overlapping PCA space, indicating highly similar epigenetic landscapes between these cell subsets irrespective of CXCR5 expression. Focusing on CXCR5, we observed an accessible open chromatin state around the CXCR5 promoter region in CXCR5^−^PD-1^+^ICOS^+^ T cells, suggesting that CXCR5^−^PD-1^+^ICOS^+^ T cells had previously been CXCR5~+~ and/or are poised for CXCR5 expression ([Figure 5D](#F5){ref-type="fig"}).

Next, we used TCF1 expression to construct a probable progression between CXCR5 positive and negative states. The transcriptional factor TCF1 is expressed at high levels by naive cells and decreases during effector cell differentiation in a cell-cycle-dependent manner ([@R22]; [@R51]). Compared to T~FH~ cells, approximately twice as many CXCR5^−^PD-1^+^ICOS^+^ T cells were CD38^+^TCF1^−^ (23.2% versus 11.3%), suggesting that the CXCR5^−^PD-1^+^ICOS^+^ phenotype enriched for activated T cells in a more differentiated state ([Figures 5E](#F5){ref-type="fig"} and [Figures 5F](#F5){ref-type="fig"}). In culture conditions, CXCR5 expression was unstable on T~FH~ cells and became downregulated following SEB-induced T cell stimulation and cell division ([Figures 5G](#F5){ref-type="fig"}, S4E, and S4F). These data support a shared differentiation program between CXCR5^−^PD-1^+^ICOS^+^ T cells and T~FH~ cells and suggest downregulation of CXCR5 as a potential mechanism that contributes to the accumulation of CXCR5^−^PD-1^+^ICOS^+^ T cells in inflamed LNs.

Transcriptomic Analyses Capture a Unique Set of Gene Signature Expressed by CXCR5^−^PD-1^+^ICOS^+^ T Cells {#S8}
----------------------------------------------------------------------------------------------------------

To begin to elucidate the functional program of CXCR5^−^ T cells, we performed transcriptomic profiling of naive, CXCR5^−^PD-1^−^ICOS^−^, CXCR5^−^PD-1^+^ICOS^+^, and T~FH~ cells by RNA sequencing (RNA-seq). PCA of the RNA-seq dataset partitioned CXCR5^−^PD-1^+^ICOS^+^T cells in a region neighboring T~FH~ cells on the PCA space, indicating considerable similarity in the global transcriptomics between these two populations ([Figure 6A](#F6){ref-type="fig"}). To identify gene programs that are unique to CXCR5^−^PD-1^+^ICOS^+^ T cells, we used gene set enrichment analysis (GSEA) to identify the Gene Ontology (GO) biological pathways enriched in CXCR5^−^PD-1^+^ICOS^+^ T cells compared to T~FH~ cells. In parallel, we identified 344 genes differentially expressed between CXCR5^−^PD-1^+^ICOS^+^ T cells and T~FH~ cells using DEseq2. We then used GOrilla to find GO biological pathways enriched by this gene set. The results from GSEA and differential gene expression analyses were combined to identify GO terms common to both analyses methods, which were consolidated by REVIGO to remove redundancy ([@R66]) ([Figure S7](#SD1){ref-type="supplementary-material"}). The pathways revealed by these analyses included processes involved in cell migration, T cell activation, and differentiation ([Figure 6B](#F6){ref-type="fig"}). Expectedly, the absence of CXCR5 protein expression predicted a low CXCR5 transcripts level in CXCR5^−^PD-1^+^ICOS^+^ T cells ([Figure 6C](#F6){ref-type="fig"}). In addition, CXCR5^−^PD-1^+^ICOS^+^ T cells showed decreased expression of other T~FH~-related genes, including BCL6 and its upstream regulator IKZF3 ([@R55]), as well as key molecules necessary for stable T cell:B cell interaction, SLAM Associated Protein/SH2 Domain Protein 1A (SH2D1A), and CD40LG ([@R1]; [@R53]). Instead, Th1-associated genes TBX21, RUNX3, and ID2 were elevated in CXCR5^−^PD-1^+^ICOS^+^ T cells ([@R24]; [@R61]; [@R67]). The list of differentially expressed pathways was also notable for migration-related processes. The transcript level of sphingosine-1-phosphate receptor 1 (S1PR1) receptor and its upstream regulator KLF2 were both increased in CXCR5^−^PD-1^+^ICOS^+^ T cells compared to T~FH~ cells ([@R64]). In addition, CXCR5^−^PD-1^+^ICOS^+^ T cells expressed high levels of genes encoding adhesion molecules, ITGB1 and SELPLG, as well as pro-inflammatory chemokine receptors that mediate migration to sites of inflammation, including CCR2, CXCR6, CCR5, CCR9, and CCR10. In spite of global transcriptomic similarities between CXCR5^−^PD-1^+^ICOS^+^ T cells and T~FH~ cells, CXCR5^−^PD-1^+^ICOS^+^ T cells were more similar to CXCR5^−^PD-1^−^ICOS^−^ and naive T cells in a targeted analysis of genes encoding trafficking-related receptors and showed the strongest upregulation of CCR5, CXCR6, and CCR2 compared to the other CD4^+^ T cell subsets ([Figures 6D](#F6){ref-type="fig"} and [S7](#SD1){ref-type="supplementary-material"}). These results indicate that CXCR5^−^PD-1^+^ICOS^+^ T cells are transcriptionally similar to T~FH~ cells on a global level but differed from T~FH~ cells by the upregulation of genes involved in cellular trafficking and a shifting balance between Th1 and T~FH~ transcriptional programs.

CXCR5^−^PD-1^+^ICOS^+^ T Cells Express a Migratory Gene Program and Contribute to CXCR5^−^PD-1^+^ICOS^+^ T Cells in the Peripheral Blood {#S9}
----------------------------------------------------------------------------------------------------------------------------------------

Because the transcriptional signatures of CXCR5^−^PD-1^+^ICOS^+^ T cells is dominated by migration-related genes, including the G-protein coupled receptor S1PR1 required for lymphocyte egress ([@R20]), we hypothesized that CXCR5^−^PD-1^+^ICOS^+^ T cells in the LNs contribute to a circulating pool of CXCR5^−^PD-1^+^ICOS^+^ T cells in the blood. To test this, we sorted CXCR5^−^PD-1^+^ICOS^+^ T cells from peripheral blood mononuclear cells (PBMCs) and compared TCR sequences from PBMC and LN cells from the same donors ([Figure S5C](#SD1){ref-type="supplementary-material"}). We hypothesized that we could capture identical TCR sequences in distinct compartments if there is trafficking of cells between blood and LNs. A comparison of the TCR repertoires showed the similarity index were indeed the highest between the TCR repertoires of blood and LN-derived CXCR5^−^PD-1^+^ICOS^+^ T cells ([Figures 7A](#F7){ref-type="fig"} and [7B](#F7){ref-type="fig"}). In addition, TCRs expressed by circulating CXCR5^−^PD-1^+^ICOS^+^ T cells also shared a significant overlap with the TCRs expressed by T~FH~ cells in the LN, suggesting a direct or indirect contribution from the T~FH~ cells.

Next, we quantified the frequency of CXCR5^−^PD-1^+^ICOS^+^ T cells in PBMC and compared it with different T cell subsets in the LN. We found that relatedness by TCR repertoire sequencing predicted shared abundance across compartments. For example, the abundance of circulating CXCR5^−^PD-1^+^ICOS^+^ T cells correlated with that of CXCR5^−^PD-1^+^ICOS^+^ T cells and T~FH~ cells in the LN. In contrast, the frequency of CXCR5^−^PD-1^+^ICOS^+^ T cells in the blood did not correlate with the frequency of lymphoid CXCR5^−^PD-1^−^ICOS^−^ T cells, with which there was little TCR overlap ([Figure 7C](#F7){ref-type="fig"}). The circulating CXCR5^−^PD-1^+^ICOS^+^ population also showed similar clinical correlation as CXCR5^−^PD-1^+^ICOS^+^ T cells in the LN and was associated with peripheral CD4^+^ T cell depletion during chronic HIV infection ([Figure 7D](#F7){ref-type="fig"}). Collectively, these data suggest that changes detected in the PBMC were reflective of the related populations in the LN.

To determine if CXCR5^−^PD-1^+^ICOS^+^ T cells isolated from the PBMC can also modulate B cell responses, naive, CXCR5^−^PD-1^−^ICOS^−^, CXCR5^−^PD-1^+^ICOS^+^, or CXCR5~+~PD-1^+^ICOS^+^ (cT~FH~) cells were sorted from PBMCs and cocultured with B cells in the presence of SEB. Consistent with past studies, the CXCR5^+^ subset in the PBMCs provided B cell help ([@R45]; [@R50]) ([Figures 7E](#F7){ref-type="fig"} and [7F](#F7){ref-type="fig"}). We also found a significantly higher level of antibody production and plasma cell differentiation by B cells in the presence of PBMC-derived CXCR5^−^PD-1^+^ICOS^+^ T cells. Taken together, these data link CXCR5^−^PD-1^+^ICOS^+^ T cells in the LN with cells in the blood and suggest that a migratory CXCR5^−^ T cell population from the LN contribute to the B cell help functionality in the PBMCs.

DISCUSSION {#S10}
==========

According to the prevailing model of T~FH~ cell differentiation, CXCR5 is expressed in early T~FH~ cells, and it remains expressed during progressive stages of T~FH~ cell differentiation ([@R17]). CD4^+^ T cells in the LNs that lacked CXCR5 expression have generally been categorized as non-T~FH~ cells. The focus on CXCR5 as a key T~FH~ cell marker is explained by its critical role in guiding T cells to the B cell zone to promote B cell differentiation and affinity maturation ([@R2]; [@R33]). CXCR5 is also the major marker used to identify circulating T~FH~ cells in the blood ([@R7]; [@R14]; [@R34]; [@R45]; [@R50]; [@R68]). The link between blood and LN-derived CXCR5^+^ T cells is supported by data from [@R35], which utilized TCR sequencing to demonstrate shared clonal relationship between CXCR5^+^PD-1^+^ T cells in the blood and T~FH~ cells from the tonsils of matched donors. A recent study by [@R68] further showed that CXCR5^+^ T~FH~ cells can traffic into blood via the thoracic duct. By analyzing primary LNs obtained from a cohort of mostly untreated HIV^+^ patients as an effort to understand T cell activation in the lymphoid environment, we provided evidence for an alternative differentiation state that gives rise to a migratory population of T~FH~-cell-related CXCR5^−^ T cells during chronic inflammation.

The existence of CXCR5^−^ CD4^+^ T cell subset that displayed T~FH~-cell-like features has been previously described by [@R52]. Using LN cells from HIV-infected patients, [@R52] highlighted T~FH~ cells as a viral reservoir of HIV infection, but intriguingly the same dataset also showed the accumulation of a CXCR5^−^PD-1^+^ population that was enriched for HIV-specific T cells, produced IL-21, and exhibited B cell helper activity *in vitro*. Our data build on these earlier observations to elucidate the functional relevance of activated CXCR5^−^PD-1^+^ICOS^+^ T cells and their relationship to other CD4^+^ T cells within LNs. We had initially hypothesized that CXCR5^−^PD-1^+^ICOS^+^ T cells in HIV-infected LNs reflected T cell exhaustion from chronic antigen stimulation. While CXCR5^−^PD-1^+^ICOS^+^ T cells indeed expressed higher levels of co-inhibitory receptors, these T cells retained the ability to produce cytokines, including IL-21. CXCR5^−^PD-1^+^ICOS^+^ T cells, including those that were HIV specific, also displayed functional capacity to promote plasma cell differentiation and antibody production *in vitro*. Because CXCR5^−^PD-1^+^ICOS^+^ T cells exhibited Th1-skewed functional characteristics, we further investigated whether accumulation of CXCR5^−^PD-1^+^ICOS^+^ T cells in inflamed LNs was associated with an increase in T-bet^+^ B cells. T-bet^+^ B cells mediate effective viral clearance in murine models of chronic infection ([@R4]; [@R57]). In humans, the contribution of T-bet^+^ B cells to anti-viral protection is less clear, but these B cells accumulate in the PBMCs of HIV-infected individuals and encompass the majority of measurable anti-Env B cell responses during HIV infection ([@R40]; [@R49]). The correlation between the frequencies of T-bet^+^ B cells and IFN-γ-producing CXCR5^−^PD-1^+^ICOS^+^ T cells in our dataset suggests the possibility that CXCR5^−^PD-1^+^ICOS^+^ T cells may promote B cell differentiation toward the T-bet^+^ subset, which will require experimental validation in future studies.

Several lines of evidence suggested that CXCR5^−^PD-1^+^ICOS^+^ and T~FH~ cells share a common clonal lineage. First, ATAC-seq analyses showed a similar epigenetic landscape between CXCR5^−^PD-1^+^ICOS^+^ T cells and T~FH~ cells and revealed an accessible open chromatin state around CXCR5 promoter region for CXCR5^−^PD-1^+^ICOS^+^ T cells; second, the TCR repertoire from CXCR5^−^PD-1^+^ICOS^+^ T cells overlapped with the repertoire of T~FH~ cells, with identical TCR beta chain (TCRβ) complementarity-determining region 3 (CDR3) sequences found in both CXCR5^+^ and CXCR5^−^ subsets; and third, CXCR5 expression became downregulated by T cell activation *in vitro*. The parsimonious explanation for our data is that activation-dependent downregulation of CXCR5 on T~FH~ cells led to the accumulation of CXCR5^−^PD-1^+^ICOS^+^ T cells. Flexibility in CXCR5 expression is consistent with studies in mice that showed the emergence of a small population of CXCR5^−^ effectors after lymphocytic choriomeningitis virus (LCMV) infection from adoptively transferred antigen-specific CXCR5^+^ T cells ([@R31]). The open chromatin state around CXCR5 promoter further indicates that CXCR5^−^PD-1^+^ICOS^+^ T cells remain permissible for CXCR5 expression and suggest the potential for reversibility of CXCR5 expression in CXCR5^−^ T cells. Our data do not rule out the possibility for the coexistence of additional processes that may be non-T~FH~-cell related. Differences in the source of precursor cells and/or the chosen differentiation pathway may further contribute to the heterogeneity of phenotypic subsets within CXCR5^−^PD-1^+^ICOS^+^ T cells, which remains to be fully elucidated.

The LN-derived CXCR5^−^ CD4^+^ T cells in our analyses appear phenotypically similar to a recently discovered peripheral CXCR5^−^ CD4^+^ T cell population characterized by CCR2 and HLA-DR expression and have the ability to promote B cell responses ([@R54]). These cells were found to localize in close proximity to B cells in the synovial lymphoid aggregates of patients with seropositive rheumatoid arthritis and have been suggested to drive ectopic antibody responses in chronically inflamed tissues ([@R54]). Another study from [@R15] identified CXCR5^−^PD-1^+^ gluten-specific T cells in the intestines and blood of patients with celiac disease. Notably, these gluten-specific T cells were enriched for CD38, HLA-DR, ICOS, and CD39 expression, which were also highly expressed by the CXCR5^−^PD-1^+^ICOS^+^ population in our dataset. As the majority of circulating CXCR5^+^ cells do not become CXCR5^−^ *in vitro* ([@R54]), the origin of peripheral CXCR5^−^PD-1^+^ T cells remains unknown. Our data on LN samples linked cells in the lymphoid and peripheral compartments by demonstrating that a population of CXCR5^−^PD-1^+^ICOS^+^ T cells acquires a migratory program in chronically inflamed LNs. Movement of expanded CXCR5^−^PD-1^+^ICOS^+^ T cells from the LN into blood could establish a pool of circulating CXCR5^−^ T cells that are poised for CXCR5 expression. Building on the insights generated by [@R54] and [@R15], we suggest that these lymphoid-derived circulating CXCR5^−^ T cells likely infiltrate inflamed tissue sites, and their unique cytokine profile could further modify the quality and the potency of ectopic B cell responses.

In summary, we have uncovered an accumulation of activated CXCR5^−^ CD4^+^ T cell subset marked by high PD-1 expression in HIV-infected LNs. Our results linked LN pathology to changes in circulating T cells. As chronic inflammatory state is a shared feature across infection and autoimmunity, the accumulation of CXCR5^−^PD-1^+^ICOS^+^ T cells in the LN may represent a general state of lymphoid dysregulation that contributes to inflammatory responses in peripheral compartments.

STAR★METHODS {#S11}
============

LEAD CONTACT AND MATERIALS AVAILABILITY {#S12}
---------------------------------------

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Laura F. Su (<Laurasu@upenn.edu>). This study did not generate new unique reagents.

EXPERIMENTAL MODEL AND SUBJECT DETAILS {#S13}
--------------------------------------

### Study Subjects {#S14}

LNs and PBMCs were obtained from HIV^+^ patients undergoing excision of palpable cervical LNs for clinical diagnostic workup in Mexico. Additional PBMCs were obtained from a second cohort of patients at the University of Pennsylvania. LNs from HIV negative donors were obtained from organ transplant donors or surgical samples. Sample sizes were not pre-specified and were dictated by the availability of the samples, which were collected over four years. All samples were de-identified and obtained with IRB regulatory approval from the University of Pennsylvania. Recruitment of HIV^+^ Mexican study subjects was additionally approved by the Comité de Ciencia y de Ética en Investigación and the Comité de Investigación of the Instituto Nacional de Enfermedades Respiratorias (INER) in México city. Subject characteristics are shown in [Table S1](#SD1){ref-type="supplementary-material"}.

### Cell culture {#S15}

Cell cultures were performed using cryopreserved cells, which were thawed in RPMI media (Mediatech) containing 0.025 unit/mL of benzonase (Sigma). Please refer to individual sections below for the specific stimulation condition used for each assay. Cells were incubated in standard conditions: 37°C with 5% CO~2~.

METHOD DETAILS {#S16}
--------------

### CyTOF staining and data analyses {#S17}

Cryopreserved cells were thawed, washed, and stimulated with 5ng/ml of PMA (Sigma) and 50ng/ml ionomycin (Sigma) in the presence of 2mM Monensin (Sigma) and 5ug/ml Brefeldin A (Sigma) at 37°C for 5 hours. After stimulation, cells were washed and incubated in 1uM cisplatin (Fluidigm) for 5 min, followed by staining with surface antibody cocktail for 30 minutes at room temperature ([Table S2](#SD1){ref-type="supplementary-material"}). For intracellular staining, cells were permeabilized and fixed using Foxp3 staining buffer set (eBioscience) and incubated with the intracellular antibody cocktail for 1 hour at room temperature ([Table S2](#SD1){ref-type="supplementary-material"}). Metal conjugation of CyTOF antibodies was performed according to the manufacturer protocol using the X8 Maxpar kit (Fluidigm). Antibody stained cells were mixed with normalization beads and acquired on CyTOF2. Bead standards were used to normalize CyTOF runs with the MATLAB-based Nolan lab normalizer ([@R27]). Iridium^+^Cisplatin^−^ cells were excluded for doublets and beads. From each sample, equal numbers of manually gated CD19^−^CD3^+^TCRγδ^−^TCRαβ^+^CD4^+^ cells were downsampled, and exported using FlowJo (Treestar). Using the R package "cytofkit," the expression values from all of the exported FCS files were arcsinh transformed and combined into a single CSV file. From this CSV file, dimensionality reduction was performed using the Python implementation of the UMAP algorithm (n = 40,000, n_neighbors = 15, metric = Euclidian, minimum distance = 0.2). The expression values of the following markers were used as the input for UMAP: CD25, IL-2, ICOS, Ki67, TCF1, PD-1, CCR7, CD45RO, CCR5, CD71, IL-4, Foxp3, CD57, perforin, CD5, granzyme B, IFN-γ, CD69, TNF-α, CD27, CXCR4, CXCR5, CD103, CCR4, CCR6, IL-13, IL-17A, CD38, and HLA-DR. The heatmap was generated using the "gplot" package in R and show the raw staining intensity of each marker after arcsinh transformation. Heatmap dendograms were clustered by Euclidean distance.

### Cell sorting and staining by flow cytometry {#S18}

For surface staining, cells were stained with antibody cocktails for 30 minutes at room temperature. Fixable aqua dye (ThermoFisher) staining was used for live/dead discrimination. T cell stimulation was performed as described above by adding PMA and ionomycin for 5 hours in the presence monensin and Brefeldin A. For intracellular cytokine or transcription factor staining, cells were permeabilized and fixed using Foxp3 staining buffer set and stained in permeabilization buffer according to vendor protocol (eBioscience). Samples were acquired on LSRII (BD Biosciences). For cell sorting, freshly thawed LN cells were separated into ICOS high or ICOS low subset by positive enrichment using a magnetic column (Miltenyi Biotec). See [Figure S5](#SD1){ref-type="supplementary-material"} for the gates used for sorting T cells and B cells. Cell sorting was performed using FACSAria III (BD Biosciences). Analyses were performed using FlowJo 10.0.8 (Tree Star).

### T:B coculture assays and antigen-specific analyses {#S19}

Memory B cells (5,000 cells/well) were cultured with T cells (5,000 cells/well) in a V-bottom plate with media supplemented with the anti-retroviral drugs Raltegravir (1uM, Cayman Chemical) and Efavorez (1uM, Cayman Chemical). For a subset of experiments that examined stability of CXCR5 expression, T~FH~ cells were stained with CFSE (3uM, Invitrogen) after sorting and prior to coculture. Cells were treated with DMSO, SEB (1ug/mL, Toxin Technology), or Gag and Env peptide pools (0.25ug/mL of \#12425 and \#12540, NIH AIDS Reagent Program). Measurements of IgG level, B and T cell phenotypes were assayed after 7 days in culture. IFN-γ level in the supernatant was measured using Luminex by the Human Immunology Core at the University of Pennsylvania. For detection of HIV-specific T cells, LN cells were incubated with 0.25ug/mL of Gag peptide pools and analyzed for OX40 and CD25 co-expression after 18 hours.

### ELISA and ELISPOT assays {#S20}

ELISA and ELISPOT were performed according to standard protocols with minor modifications ([@R56]; [@R58]). Briefly, anti-human IgG (1:100, Bethyl), pooled Gag and Env peptides (5ug/mL, \#12425 and \#12540 NIH AIDS Reagent Program) or recombinant Gag and Env proteins (0.4ug/mL, \#7749, \#11784, \#12028, \#13126, \#12577 NIH AIDS Reagent Program) were coated on 96-well MaxiSorp-Immuno microplates (Nunc). Plate bound IgG from the culture supernatants or IgG standards (Sigma) were detected using biotinylated anti-IgG (1:2000, BD), followed by streptavidin-HRP (1:2000, Southern Biotech) and the addition of TMB substrate (Biolegend) for colorimetric readout at OD450 using the Synergy HT plate reader (Biotek). Polyclonal goat antiserum (2:1000, \#38 NIH AIDS Reagent Program) was used as positive control for HIV-specificity and detected using anti-Goat Igg-HRP (1:1000, Santa Cruz Biotech). For ELISPOT, 96-well MultiScreenHTS IP Filter plates (Millipore) were coated with goat anti-human kappa/lambda (Southern Biotech), Gag/Env peptide pool (\#12425 and \#12540, NIH AIDS Reagent Program), or HIV-1 recombinant proteins (\#7749, \#11784, \#12028, \#13126, \#12577, NIH AIDS Reagent Program) at the final concentration of 5ug/mL in PBS and blocked using RPMI 1640 containing 10% fetal calf serum (FCS). On day 5 of cocultures, B cells from each stimulation condition were equally distributed across PBS or antigen-coated wells and incubated for 6 hours at 37°C. ASC were detected using biotinylated mouse anti-human IgG antibody (1:1000, BD), followed by streptavidin-HRP (1:1000, Southern Biotech). Spots were developed using TMB substrate (Mabtech) and enumerated with an automated Immunospot S6 core analyzer and software (Cellular Technology).

### TCRβ sequencing and analyses {#S21}

TCR library generation and sequencing on FACS-sorted T cells was performed as previously described ([@R69]). Briefly, FACS-sorted cells were lysed, and total RNA was purified using AllPrep DNA/RNA Micro Kit (QIAGEN). 30% of the purified RNA was used for library generation and sequencing. Consensus sequences were constructed within each molecular identifier (MID) group ([@R48]). Consensus TCR sequences were subjected to the CDR3 blast module of MIGEC ([@R62]) to assign V and J alleles and parse out the CDR3 sequence. Bhattacharyya coefficient was used to measure TCR repertoire similarity between CXCR5^−^PD-1^+^ICOS^+^ T cells with other populations within LN and between CXCR5^−^PD-1^+^ICOS^+^ T cells in the PBMC and LN subsets ([@R8]). Circos plots were generated using circlize R package to visualize clones shared between T cell subsets.

### ATAC-seq and analyses {#S22}

ATAC-seq was performed as previously described with minor modifications ([@R11]). In brief, sorted T cells were pelleted and resuspended in 50uL lysis buffer (10 mM Tris-HCl \[pH 7.4\], 10 mM NaCl,3 mM MgCl2, 0.1% IGEPAL CA-630). Transposition reaction was carried out immediately in a 25uL reaction with 1.25uL of Tn5 transposase (Illumina) in a 37°C water bath for 37 minutes to tag and fragment accessible chromatin. Tagmented DNA was purified using a MinElute Reaction Cleanup Kit (QIAGEN) and amplified with 12 cycles of PCR. Libraries were purified using Agencourt AMPure XP kit (Axygen). Sample quality was determined using a Tapestation 2200 system (Agilent). Library concentrations were determined using Qubit dsDNA HS Assay Kit (Invitrogen). Libraries were paired-end sequenced on a NextSeq 550 (Illumina). All the reads are quality-trimmed with trimmomatic-0.36-5 (see [Table S3](#SD1){ref-type="supplementary-material"}). The paired-end reads were aligned to human assembly hg19 using bowtie alignment tool (bowtie2-2.3.4.1). The peaks were called using callpeaks function in MACS2. Peaks called with a q-value cutoff of 0.05 (Benjamin-Hochberg correction) were analyzed with DiffBind R package. The intervals for peak comparison were re-centered around the most enriched points with a 500-bp window. The consensus peaksets were then normalized and used as input for differential analysis by DESeq2 with a significance cutoff FDR at 0.05 (Benjamin-Hochberg correction). DiffBind was used to generate the PCA plot.

### RNA sequencing and analyses {#S23}

Sorted T cells were pelleted and resuspended in Buffer RLT Plus (QIAGEN) with 10% 2-Mercaptoethanol (Sigma). Total RNA from each sample was isolated using the RNeasy Plus Micro Kit (QIAGEN). RNA integrity was determined using a 2100 Bioanalyzer (Agilent). Reverse transcription and cDNA synthesis was performed using the SMART-Seq v4 Ultra Low Input RNA Kit for Sequencing (Clontech). cDNA qualities were determined by a Tapestation 2200 system (Agilent) and concentrations were determined using Qubit dsDNA HS Assay Kit (Invitrogen). DNA libraries were prepared using Nextera XT Library Prep Kit (Illumina) and sequenced on NextSeq 550 (Illumina). All the reads are quality-trimmed with trimmomatic-0.36-5. The paired-end reads were aligned to human assembly hg19 using STAR alignment tool (STAR 2.6). For finding differential expressed genes between samples, DESeq2 R packaged was used to calculate variation, with a significance cutoff padj at 0.05 (Benjamin-Hochberg correction). PCA analysis was performed using plotPCA function in DESeq2 R package. The variant genes were then submitted to GOrilla for gene ontology analysis. Gene Set Enrichment Analysis (GSEA) was performed to compare the enriched genes in CXCR5^+^PD-1^+^ / CXCR5^−^PD-1^+^ T cells. The significant hit from GSEA and Gorilla were matched to generate a list of enriched gene ontologies consistently identified by both methods. The GO list was then revised by removing redundant terms with REVIGO ([@R66]), shortening the list from 25 to 8. Scaled normalized expression values were used as input for generating supervised hierarchical clustering heatmap for differentially expressed genes that contributed to the GO terms and for generating the volcano plot.

QUANTIFICATION AND STATISTICAL ANALYSIS {#S24}
---------------------------------------

Assessment of normality was performed using D'Agostino-Pearson test. Pearson or Spearman correlation was used depending on the normality of the data to measure the degree of association. The best-fitting line was calculated using least-squares fit regression. Statistical comparisons were performed using two-tailed Student's t test, Mann-Whitney U test, or Wilcoxon signed-rank test, using a p value of \< 0.05 as a cutoff to determine statistical significance. Multiple-way comparisons were performed using ANOVA or nonparametric tests (Friedman test for matched measures or Kruskal-Wallis test for unmatched measures). Statistical analyses were performed using GraphPad Prism. Lines and bars represent mean, variability is represented by standard error of the mean (SEM). \* *p* \< 0.05; \*\* *p* \< 0.005; \*\*\* *p* \< 0.0005. \*\*\*\* *p* \< 0.0005.

DATA AND CODE AVAILABILITY {#S25}
--------------------------

The data for this study have been deposited in the database dbGAP under accession number phs001548.v1.p1 (dbGAP: phs001548.v1.p1).
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![High-Dimensional Analyses of Activated T Cells in HIV-Infected LNs\
(A--E) CyTOF analyses of 8 HIV-infected LNs.\
(A) Representative plot and bar graph show the relative contribution of major T cell subsets in HIV-infected LNs by TCR and co-receptor expression.\
(B) Plot summarizes fold change over mean signal intensity for differentially expressed markers between CD38^−^HLA-DR^−^ and CD38^+^HLA-DR^+^ CD3^+^ T cells.\
(C) UMAP displays of PD-1 and CXCR5 staining on CD4^+^ T cells using concatenated data from 8 HIV LN samples.\
(D) Heatmap shows the average staining signal of individual markers for each CD4^+^ T cell subset as indicated. Markers used to select input cells were excluded.\
(E) Representative plot showing PD-1 and CD38 co-staining.\
(F--J) Flow cytometry analyses of 7 HC and 9 HIV LNs.\
(F) Plots showing subdivision of CD4^+^ T cells by CXCR5 and PD-1 staining on a representative HC or HIV-infected LN sample.\
(G) Bar graph quantifies the frequency of each phenotypic subset in HC or HIV-infected LNs.\
(H) The frequency of CD38^+^ T cells within each manually gated CD4^+^ T cell subset.\
(I) The frequency of CD38^+^ T cells within ICOS^−^ versus ICOS^+^ subset of CXCR5^−^PD-1^++^ T cells.\
(J) Correlation between peripheral CD4:CD8 ratio of 22 HIV^+^ donors and the frequency of CXCR5^−^PD-1^+^ICOS^+^ subset of CD4^+^ T cells in their LNs.\
For (B) and (G), differentially expressed markers were selected using multiple t tests and corrected using Holm-Sidak method. For (H), Friedman test was performed and corrected using Dunnett's multiple comparisons test. For (I), paired t test was used. Association for (J) was measured by Pearson correlation. Data are represented as mean ± SEM.\
Also see [Figures S1](#SD1){ref-type="supplementary-material"} and [S2](#SD1){ref-type="supplementary-material"}.](nihms-1542908-f0001){#F1}

![Co-inhibitory Receptor Expression and the Functional Potential of CD4^+^ T Cell Subsets in HIV-Infected LNs\
(A) Relative expression of the indicated co-inhibitory receptors as a percentage of indicated subsets (n = 8).\
(B) Representative staining for IFN-γ and TNF-α in PD-1^−^ and PD-1^+/++^ T cells. PD-1^−^ cells combined CXCR5^−^PD-1^−^ and CXCR5^+^PD-1^−^ subsets. PD-1^+/++^ cells included both CXCR5^−^ and CXCR5^+^ cells of intermediate (PD-1^+^) and high PD-1 expression (PD-1^++^).\
(C) The frequency of cells in individual subsets that positively stained for the indicated cytokines after PMA and ionomycin stimulation (n = 8).\
(D) The frequency of IL-21^+^ T cells in the indicated subsets following stimulation as measured by CyTOF (n = 25).\
For (A), Friedman test was applied and corrected using Dunn's multiple comparison test. For (C), two-way ANOVA was performed. Mean of each subset were compared to that of CXCR5^−^PD-1^−^ T cells and corrected using Dunnett's multiple comparisons test. For (D), one-way ANOVA was performed and corrected using Holm-Sidak method. Data are represented as mean ± SEM.\
Also see [Figures S3](#SD1){ref-type="supplementary-material"} and [S4A](#SD1){ref-type="supplementary-material"}--[S4C](#SD1){ref-type="supplementary-material"}.](nihms-1542908-f0002){#F2}

![CXCR5^−^PD-1^+^ICOS^+^ T Cells in HIV-Infected LNs Express T~FH~-Cell-Related Proteins and Function\
(A) Histograms showing fluorescent intensity of BCL6, Maf, and CD84 staining in naive (1), CXCR5^−^PD-1^−^ICOS^−^ (2), CXCR5^−^PD-1^+^ICOS^+^ (3), and T~FH~ cells (4). Plots summarize data from 8 HIV LNs.\
(B) Plasma cell phenotype of B cells cocultured with the indicated T cell subsets without or with SEB.\
(C-E) Quantification of total IgG (n = 13) (C), plasma cells (n = 15) (D), or CD4^+^ T cells (n = 15) (E) on the 7^th^ day of each coculture condition.\
(F) IFN-γ level in the supernatant of wells containing T~FH~ cells or CXCR5^−^PD-1^+^ICOS^+^ T cells (n = 9).\
(G) Example gate for T-bet^+^ B cells. Naive IgD^+^CD27^−^ B cells were excluded. Scatterplot quantifies T-bet^+^ B cells in 7 HC and 25 HIV-infected LNs.\
(H) Correlation between IFN-γ expression in CXCR5^−^PD-1^+^ICOS^+^ T cells and T-bet^+^ B cell frequency in HIV-infected LN samples.\
For (A) and (C)--(E), Friedman test was performed and corrected using Dunn's multiple comparisons test. For (F), Wilcoxon matched-pairs signed rank test was used. For (G), Mann-Whitney test was used. For (H), association was measured by Spearman correlation. Data are represented as mean ± SEM.\
Also see [Figures S4D](#SD1){ref-type="supplementary-material"} and [S5A](#SD1){ref-type="supplementary-material"}.](nihms-1542908-f0003){#F3}

![CXCR5^−^PD-1^+^ICOS^+^ T Cells Contain HIV-Specific T Cells that Are Capable of Promoting Both HIV-Specific and Non-HIV-Specific Antibody Responses\
(A) Gag-specific T cells within CXCR5^−^PD-1^+^ICOS^+^ T cells or T~FH~ cells were identified by OX40 and CD25 expression in LN cells stimulated with pooled Gag peptides for 18 h. Plots show representative data from one HIV LN.\
(B) Quantification of CD25hiOX40hi T cell frequency. Background level of CD25hiOX40hi T cells in vehicle-treated wells was subtracted from Gag-stimulated wells (n = 7).\
(C) Plasma cell phenotype of B cells cocultured with the indicated T cell subsets in the presence of Gag/Env peptides for 7 days. Representative data from one individual is shown.\
(D and E) Quantification of IgG concentration (D) or plasma cell number (E) in T:B cell cocultures after 7 days of Gag/Env peptide stimulation (n = 15).\
(F) Summary plot comparing total IgG antibody concentration with concentration of antibodies that recognize Gag/Env peptides or proteins. Cocultures contained either CXCR5^−^PD-1^+^ICOS^+^ T cells or T~FH~ cells and were stimulated by Env/Gag peptides.\
(G) Bar graphs show the concentration of antibodies specific for Gag/Env protein asapercentage of total IgG produced by B cells in the presence of HIV peptide-stimulated CXCR5^−^PD-1^+^ICOS^+^ T cells or T~FH~ cells. Each bar indicates one individual.\
Friedman test was performed and corrected using Dunn's multiple comparisons test. Data are represented as mean ± SEM.\
Also see [Figure S6](#SD1){ref-type="supplementary-material"}.](nihms-1542908-f0004){#F4}

![CXCR5^−^PD-1^+^ICOS^+^ T Cells Are Clonally Related to T~FH~ Cells and Exhibit Epigenetic Similarities\
(A) Circos plots of TCR sequence overlap among different populations. Each thin slice of the arc represents a unique TCR sequence, ordered by the clone size (darker green for larger clones, inner circle). Outer circle indicate TCR sequences found in naive, CXCR5^−^PD-1^−^ICOS^−^, CXCR5^−^PD-1^+^ICOS^+^, and T~FH~ cells. Each plot represents data from one individual.\
(B) Bhattacharyya coefficient measurement for the TCR repertoire similarity between CXCR5^−^PD-1^+^ICOS^+^ T cells and other populations within LN. Grey lines connect samples from the same patient (n = 9).\
(C) Principal-component analysis of ATAC-seq data of LN CD4^+^ T cell subsets from 6 HIV^+^ donors. Each symbol represents cells from one donor; cells of the same type are coded by the same color.\
(D) Representative chromatin accessibility at the CXCR5 upstream region for each CD4^+^ T cell subset.\
(E) Example plots showing TCF1 and CD38 staining.\
(F) Quantification of activated TCF1^−^ T cells among CXCR5^−^PD-1^+^ICOS^+^ T cells and T~FH~ cells in HIV^+^ LNs (n = 8).\
(G) Sorted T~FH~ cells were labeled with carboxyfluorescein succinimidyl ester (CFSE) and treated with SEB or DMSO for 7 days in the presence of B cells. Bar graph quantifies the fluorescence intensity of CXCR5 staining on T~FH~ cells. Cell division was measured by dilution of CFSE staining (n = 6).\
For (B) and (G), Friedman test was performed and corrected using Dunn's multiple comparisons test. For (F), paired t test was used. Data are represented as mean ± SEM.\
Also see [Figures S5A](#SD1){ref-type="supplementary-material"}, [S5B](#SD1){ref-type="supplementary-material"}, [S4E](#SD1){ref-type="supplementary-material"}, and [S4F](#SD1){ref-type="supplementary-material"}.](nihms-1542908-f0005){#F5}

![CXCR5^−^PD-1^+^ICOS^+^ T Cells from HIV-Infected LNs Exhibit a Distinct Gene Expression Profile\
(A) Principal-component analysis of RNA-seq data from different CD4^+^ T cell subsets.\
(B) A list of Gene Ontologies based on significantly variant genes compared between CXCR5^−^PD-1^+^/CXCR5^+^PD-1^+^ T cells called by both GSEA and GOrilla. Normalized enrichment score (NES) and false discovery rate (FDR) were generated from GSEA. A positive enrichment score indicates gene set enrichment in CXCR5^−^PD-1^+^ICOS^+^ T cells.\
(C) Volcano plot for comparison between T~FH~ cells and CXCR5^−^PD-1^+^ICOS^+^ cells. The differentially expressed genes were defined with cutoff adjusted p value \< 0.05, log~2~ \|foldchange\| \> 1.5.\
(D) Heatmap representing differentially expressed trafficking-related receptors in 4 cell subsets. Gene expression values were normalized and scaled with DESeq2.\
Also see [Figure S7](#SD1){ref-type="supplementary-material"}.](nihms-1542908-f0006){#F6}

![CXCR5^−^PD-1^+^ICOS^+^ T Cells in the Blood Are Clonal Relatives of Cells in the LNs\
(A) Circos plots of TCR sequence overlap among different populations. Each thin slice of the arc represents a unique TCR sequence. Each plot represents data from one individual.\
(B) Bhattacharyya coefficient measurement for the TCR repertoire similarity between CXCR5^−^PD-1^+^ICOS^+^ T cells in the PBMC and the indicated T cell subsets from the LN. Similarity with naive cells was used as the baseline for comparison (n = 6).\
(C) Correlation between CXCR5^−^PD-1^+^ICOS^+^ T cells in the PBMC versus different LN subsets (n = 12 paired PBMC and LNs).\
(D) Correlation between CXCR5^−^PD-1^+^ICOS^+^ T cells in the PBMC and CD4:CD8 ratio. Data are from 12 HIV^+^ patients.\
(E) Sorted CD4^+^ T cell subsets from the PBMCs of HIV-infected individuals were cultured with B cells in the presence of SEB for 7 days. Plots show representative staining for plasma cells in cocultures.\
(F) Scatterplot quantifies IgG level and plasma cell number in cocultures with naive T cells (n = 11), CXCR5^−^PD-1^−^ICOS^−^ T cells (n = 10), CXCR5^−^PD-1^+^ICOS^+^ T cells (n = 9), or cT~FH~ cells (n = 7).\
For (B), Friedman test was performed and corrected using Dunn's multiple comparisons test. For (C) and (D), association was measured by Pearson correlation.\
For (F), Kruskal-Wallis test was performed and corrected using Dunn's multiple comparisons test. Data are represented as mean ± SEM.](nihms-1542908-f0007){#F7}

###### 

KEY RESOURCES TABLE

  REAGENT or RESOURCE                                                               SOURCE                        IDENTIFIER
  --------------------------------------------------------------------------------- ----------------------------- ------------------------------------------------------------------------------------------
  Antibodies                                                                                                      
  anti-human ICOS, APC, clone C398.4A                                               Biolegend                     Cat\# 313510; RRID:AB_416334
  anti-human PD1, BV785, clone: EH12.2H7                                            Biolegend                     Cat\# 329930; RRID:AB_2563443
  anti-human CXCR5, PE/Dazzle 594, clone J252D4                                     Biolegend                     Cat\# 356928; RRID:AB_2563689
  anti-human CD19, PE/cy5, clone HIB19                                              Biolegend                     Cat\# 302210; RRID:AB_314240
  anti-human CD45RO, BV421, clone UCHL1                                             Biolegend                     Cat\# 304224; RRID:AB_2563817
  anti-human CD45RA, PE, clone HI100                                                Biolegend                     Cat\# 304146; RRID:AB_2564079
  anti-human CD4, FITC, clone OKT4                                                  Biolegend                     Cat\# 317408; RRID:AB_571951
  anti-human CD27, APC/Fire 750, clone M-T271                                       Biolegend                     Cat\# 356428; RRID:AB_2616711
  anti-human CCR7, PE/Cy7, clone G043H7                                             Biolegend                     Cat\# 353226; RRID:AB_11126145
  anti-human CD3, AF700, clone UCHT1                                                Biolegend                     Cat\# 300424; RRID:AB_493741
  anti-human CD8, BV605, clone RPA-T8                                               Biolegend                     Cat\# 301040; RRID:AB_2563185
  anti-human CD20, BV650, clone 2H7                                                 Biolegend                     Cat\# 302336; RRID:AB_2563806
  anti-human IgD, BV605, clone IA6-2                                                Biolegend                     Cat\# 348232; RRID:AB_2563337
  anti-human CD3, FITC, clone UCHT1                                                 Biolegend                     Cat\# 300440; RRID:AB_2562046
  anti-human CD4, PE, clone OKT4                                                    Biolegend                     Cat\# 317410; RRID:AB_571955
  anti-human CD38, PE/Cy7, clone HIB7                                               Biolegend                     Cat\# 356608; RRID:AB_2561904
  anti-human CD38, AF700, clone HIB7                                                Biolegend                     Cat\# 303524; RRID:AB_2072781
  anti-human CD40L, PE/Cy7, clone 24-31                                             Biolegend                     Cat\# 310832; RRID:AB_2563017
  anti-human TIM3, SuperBright 702, clone F38-2E2                                   eBioscience                   Cat\# 67-5870-82; RRID:AB_2744892
  anti-human CD39, APC/Cy7, clone A1                                                Biolegend                     Cat\# 303534; RRID:AB_2561605
  anti-human TIGIT, PE, clone A15153G                                               Biolegend                     Cat\# 372704; RRID:AB_2632730
  anti-human 2b4, PerCP/Cy5.5, clone C1.7                                           Biolegend                     Cat\# 329516; RRID:AB_10919138
  anti-human PD1, BV605, clone EH12.2H7                                             Biolegend                     Cat\# 329924; RRID:AB_2563212
  anti-human CD45RO, BV785, clone UCHL1                                             Biolegend                     Cat\# 304234; RRID:AB_2563819
  anti-human CD84, FITC, clone CD84.1.21                                            Invitrogen                    Cat\# A15762; RRID:AB_2534542
  anti-human CCR2, PE/Cy7, clone K036C2                                             Biolegend                     Cat\# 357212; RRID:AB_2562619
  anti-human ICOS, PE, clone C398.4A                                                Biolegend                     Cat\# 313508; RRID:AB_416332
  anti-human HLA-DR, APC, clone L234                                                Biolegend                     Cat\# 307610; RRID:AB_314688
  anti-human CD3, APC/Cy7, clone UCHT1                                              Biolegend                     Cat\# 300426; RRID:AB_830755
  anti-human CD4, BV650, clone OKT4                                                 Biolegend                     Cat\# 317436; RRID:AB_2563050
  anti-human BCL6, BV421, clone K112-91                                             BD                            Cat\# 563363; RRID:AB_2738159
  anti-human c-Maf, PerCP-eFluor 710, clone sym0F1                                  Invitrogen                    Cat\# 46-9855-42; RRID:AB_2573908
  anti-human Ox40, PerCP/Cy5.5, clone Ber-ACT35 (ACT35)                             Biolegend                     Cat\# 350018; RRID:AB_2571938
  anti-human CD25, BV650, clone BC96                                                Biolegend                     Cat\# 302634; RRID:AB_2563807
  anti-human CD3, BV605, clone UCHT1                                                Biolegend                     Cat\# 300460; RRID:AB_2564380
  anti-human TCR gamma/delta, PE, clone 5A6.E9                                      Invitrogen                    Cat\# MHGD04; RRID:AB_10374518
  anti-Human IgG-F(ab')2 Fragment cross-adsorbed Antibody, polyclonal               Bethyl                        Cat\# A80-249A; RRID:AB_10630752
  anti-human IgG, Biotinylated, clone G18-145                                       BD                            Cat\# 555785; RRID:AB_396120
  anti-human IgM, PerCP/Cy5.5, clone MHM-88                                         Biolegend                     Cat\# 314512; RRID:AB_2076098
  anti-human IgG, APC, clone M1310G05                                               Biolegend                     Cat\# 410712; RRID:AB_2565790
  anti-human CD11c, BV421, clone 3.9                                                BD                            Cat\# 565806
  anti-human CD85j, PE/Cy7, clone GHI/75                                            Biolegend                     Cat\# 333712; RRID:AB_2564606
  anti-human Tbet, PE, clone 4B10                                                   Biolegend                     Cat\# 644810; RRID:AB_2200542
  anti-human Kappa, Unconjugated, polyclonal                                        Southern Biotech              Cat\# 2060-01; RRID:AB_2795716
  anti-human Lambda, Unconjugated, polyclonal                                       Southern Biotech              Cat\# 2070-01; RRID:AB_2795749
  anti-human CD57, clone HCD57                                                      Biolegend                     Cat\# 322325; RRID:AB_2563757
  anti-human CD3, clone UCHT1                                                       Biolegend                     Cat\# 300402; RRID:AB_314056
  anti-human CD5, clone UCHT2                                                       Biolegend                     Cat\# 300602; RRID:AB_314088
  anti-human CD8, clone SK1                                                         Biolegend                     Cat\# 344702; RRID:AB_1877104
  anti-human CD4, clone SK3                                                         Biolegend                     Cat\# 344602; RRID:AB_1937277
  anti-human CD19, clone HIB19                                                      Biolegend                     Cat\# 302202; RRID:AB_314232
  anti-human Granzyme B, clone CLB-GB11                                             eBioscience                   Cat\# MA1-10338; RRID:AB_11154492
  anti-human IFNg, clone 4S.B3                                                      eBioscience                   Cat\# 14-7319-81; RRID:AB_468477
  anti-human HLA-DR, clone L243                                                     Biolegend                     Cat\# 307602; RRID:AB_314680
  anti-human CD14, clone M5E2                                                       Biolegend                     Cat\# 301802; RRID:AB_314184
  anti-human CD69, clone FN50                                                       Biolegend                     Cat\# 310902; RRID:AB_314837
  anti-human CD38, clone HB-7                                                       Biolegend                     Cat\# 356602; RRID:AB_2561794
  anti-human TNFa, clone MAb11                                                      Biolegend                     Cat\# 502902; RRID:AB_315254
  anti-human CD45RO, clone UCHL1                                                    Biolegend                     Cat\# 304202; RRID:AB_314418
  anti-human CD27, clone LG.7F9                                                     eBioscience                   Cat\# 14-0271-82; RRID:AB_467183
  anti-human TCRab, clone T10B9.1A-31                                               BD                            Cat\# 555546; RRID:AB_395930
  anti-human CCR5, clone J418F1                                                     Biolegend                     Cat\# 359102; RRID:AB_2562457
  anti-human CD71, clone CY1G4                                                      Biolegend                     Cat\# 334102; RRID:AB_1134247
  anti-human CXCR4, clone 12G5                                                      Biolegend                     Cat\# 306502; RRID:AB_314608
  anti-human IL4, clone 8D4-8                                                       BD                            Cat\# 556917; RRID:AB_398620
  anti-human CD25, clone M-A251                                                     BD                            Cat\# 555430; RRID:AB_395824
  anti-human IL2, clone MQ1-17H12                                                   Biolegend                     Cat\# 500302; RRID:AB_315089
  anti-human ICOS, clone c398-4A                                                    Biolegend                     Cat\# 313502; RRID:AB_416326
  anti-human Ki-67, clone B56                                                       BD                            Cat\# 556003; RRID:AB_396287
  anti-human Foxp3, clone PCH101                                                    eBioscience                   Cat\# 14-4776-82; RRID:AB_467554
  anti-human TCF1, clone C63D9                                                      Cell Signaling                Cat\# 2203; RRID:AB_2199302
  anti-human PD1, clone EH12.2H7                                                    Biolegend                     Cat\# 329902; RRID:AB_940488
  anti-human CCR7, clone G043H7                                                     Biolegend                     Cat\# 353202; RRID:AB_10945157
  anti-human CXCR5, clone RF8B2                                                     BD                            Cat\# 552032; RRID:AB_394324
  anti-phycoerythrin (PE), clone PE001                                              Biolegend                     Cat\# 408102; RRID:AB_2168924
  anti-human CD103, clone B-Ly7                                                     eBioscience                   Cat\# 14-1038-82; RRID:AB_467412
  anti-human CCR4, clone 1G1                                                        BD                            Cat\# 551121; RRID:AB_2074502
  anti-human CCR6, clone G034E3                                                     Biolegend                     Cat\# 353402; RRID:AB_10918625
  anti-human IL13, clone JES10-5A2                                                  Biolegend                     Cat\# 501902; RRID:AB_315197
  anti-human Perforin, clone DG9                                                    Biolegend                     Cat\# 308102; RRID:AB_314700
  anti-human IL17A, clone BL168                                                     Biolegend                     Cat\# 512302; RRID:AB_961399
  mouse anti-goat IgG-HRP                                                           Santa Cruz Biotec             Cat\# sc-2354; RRID:AB_628490
  Anti-HIV-1 IIIB gp120 Polyclonal goat serum                                       NIH AIDS Reagent Program      Cat\# 38
  Biological Samples                                                                                              
  LN and PBMC samples, see [Table S1](#SD1){ref-type="supplementary-material"}      This paper                    N/A
  Chemicals, Peptides, and Recombinant Proteins                                                                   
  Phorbol 12-myristate 13-acetate (PMA)                                             Sigma-Aldrich                 Cat\# P8139
  Antibody Stabilizer                                                               Candor                        Cat\# 131050
  Ionomycin                                                                         Sigma-Aldrich                 Cat\# I0634
  BrefeldinA                                                                        Sigma-Aldrich                 Cat\# B7651-5MG
  Monesin                                                                           Sigma-Aldrich                 Cat\# M5273-1G
  Iridium (Cell-ID Intercalator-Ir 500 μM)                                          Fluidigm                      Cat\# 201192B
  Paraformaldehyde 16%                                                              Fisher                        Cat\# 50-980-487
  TCEP                                                                              Thermofisher                  Cat\# PI77720
  Cell-ID Cisplatin                                                                 Fluidigm                      Cat\# 201064
  DPBS without Ca^2+^ & Mg++                                                        Invitrogen                    Cat\# 14190136
  FBS                                                                               Sigma-Aldrich                 Cat\# F2442-500ML
  EDTA                                                                              Invitrogen                    Cat\# 15575020
  Non-essential Amino Acids                                                         Invitrogen                    Cat\# 11140050
  Sodium Pyruvate                                                                   Invitrogen                    Cat\# 11360070
  HEPES Buffer                                                                      Invitrogen                    Cat\# 15630080
  Pen/Strep Solution                                                                Invitrogen                    Cat\# 15140122
  RPMI                                                                              Mediatech                     Cat\# MT10-040-CM
  Raltegravir                                                                       Cayman Chemical               Cat\# 16071
  Efavorez                                                                          Cayman Chemical               Cat\# 14412
  Staphylococcal Enterotoxin B                                                      Toxin Technology              Cat\# BT202
  Bovine Serum Albumin                                                              Sigma-Aldrich                 Cat\# A7906
  Tween 20                                                                          Sigma-Aldrich                 Cat\# P1379
  Phosphoric acid (H3PO4)                                                           Sigma-Aldrich                 Cat\# Y0626-250G
  2-Mercaptoethanol                                                                 Sigma-Aldrich                 Cat\# M6250-100ML
  Tris-HCl                                                                          Invitrogen                    Cat\# 15567-027
  NaCl                                                                              Sigma-Aldrich                 Cat\# S5886-1KG
  MgCl2                                                                             Sigma-Aldrich                 Cat\# M8266-100G
  IGEPAL CA-630                                                                     Sigma-Aldrich                 Cat\# I8896-50ML
  Gag peptide pool                                                                  NIH AIDS Reagent Program      Cat\# 12425
  Env peptide pool                                                                  NIH AIDS Reagent Program      Cat\# 12540
  HIV-1 CN54 GP120 Recombinant protein                                              NIH AIDS Reagent Program      Cat\# 7749
  HIV-1 IIIB gp120 Recombinant protein                                              NIH AIDS Reagent Program      Cat\# 11784
  HIV-1 IIIB p24 Recombinant protein                                                NIH AIDS Reagent Program      Cat\# 12028
  HIV-1 HXB2 p24 Recombinant protein                                                NIH AIDS Reagent Program      Cat\# 13126
  HIV-1 gp140 Recombinant protein                                                   NIH AIDS Reagent Program      Cat\# 12577
  Critical Commercial Assays                                                                                      
  LIVE/DEAD Fixable Aqua Dead Cell Stain Kit                                        Invitrogen                    Cat\# L34957
  FoxP3 Transcription factor staining kit                                           Thermofisher                  Cat\# A25866A
  Maxpar X8 Multimetal Labeling Kit                                                 Fluidigm                      Cat\# 201300
  EQ Four Element Calibration Beads                                                 Fluidigm                      Cat\# 201078
  Anti-APC MicroBeads                                                               Miltenyi                      Cat\# 130-090-855
  LS Columns                                                                        Miltenyi                      Cat\# 130-042-401
  MACS MultiStand                                                                   Miltenyi                      Cat\# 130-042-303
  QuadroMACS Separator                                                              Miltenyi                      Cat\# 130-090-976
  CellTrace CFSE Cell Proliferation Kit                                             Invitrogen                    Cat\# C34554
  SA-HRP                                                                            Southern Biotech              Cat\# 7100-05
  TMB Substrate Set                                                                 Biolegend                     Cat\# 421101
  Buffer RLT Plus                                                                   QIAGEN                        Cat\# 1053393
  RNeasy Plus Micro Kit                                                             QIAGEN                        Cat\# 74034
  Arcturus Picopure RNA Isolation Kit                                               Applied Biosystems            Cat\# KIT0204
  SMART-Seq® v4 Ultra® Low Input RNA Kit for Sequencing                             Takara                        Cat\# 634894
  Qubit dsDNA HS Assay Kit                                                          Invitrogen                    Cat\# Q32851
  Nextera XT Library Prep Kit                                                       Illumina                      Cat\# FC-131-1096
  Nextseq 500/550 High Output Kit v2 (75 cycles)                                    Illumina                      Cat\# FC-404-2005
  Agencourt AMPure XP kit                                                           Beckman Coulter               Cat\# A63880
  Nextera DNA Library Prep Kit                                                      Illumina                      Cat\# FC-121-1030
  MinElute Reaction Cleanup Kit                                                     QIAGEN                        Cat\# 28204
  Agencourt AMPure XP kit                                                           Beckman Coulter               Cat\# A63880
  Nextseq 500/550 High Output Kit v2 (75 cycles)                                    Illumina                      Cat\# FC-404-2005
  Allprep DNA/RNA micro kit                                                         QIAGEN                        Cat\# 80284
  Superscript III Reverse Transcriptase                                             Invitrogen                    Cat\# 18080093
  Exonuclease I                                                                     New England Biolabs           Cat\# M0293S
  Takara Ex Taq HS DNA Polymerase                                                   Clontech                      Cat\# RR006B
  MiniElute Reaction Cleanup Kit                                                    QIAGEN                        Cat\# 28204
  E-Gel NGS 0.8% Agarose Gels                                                       Invitrogen                    Cat\# A25798
  TMB substrate                                                                     Mabtech                       Cat\# 3651-10
  Deposited Data                                                                                                  
  dbGAP                                                                             This paper                    phs001548.v1.p1
  Oligonucleotides                                                                                                
  TCR sequencing primers, see [Table S4](#SD1){ref-type="supplementary-material"}   This paper                    N/A
  Software and Algorithms                                                                                         
  Synergy HT Plate Reader                                                           Biotek                        7091000
  FlowJo v10.0.8                                                                    Treestar                      N/A
  GraphPad Prism v6.0c                                                              <https://www.graphpad.com/>   N/A
  Cytof Bead Normalizer                                                             [@R27]                        N/A
  Cytofkit                                                                          [@R13]                        <https://www.ncbi.nlm.nih.gov/pubmed/27662185>
  gplots                                                                                                          <https://rdrr.io/cran/gplots/>
  UMAP                                                                              [@R6]                         <https://arxiv.org/pdf/1802.03426.pdf>
  Immunospot S6 core analyzer                                                       Cellular Technology           N/A
  MIGEC                                                                             [@R62]                        <https://www.nature.com/articles/nmeth.2960>
  Circlize                                                                          [@R30]                        <https://www.ncbi.nlm.nih.gov/pubmed/24930139>
  trimmomatic-0.36-5                                                                [@R10]                        <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4103590/>
  bowtie2-2.3.4.1                                                                   [@R43]                        <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3322381/>
  DiffBind                                                                                                        <http://bioconductor.org/packages/release/bioc/html/DiffBind.html>
  DESeq2                                                                            [@R47]                        <https://genomebiology.biomedcentral.com/articles/10.1186/s13059-014-0550-8>
  STAR 2.6                                                                          [@R25]                        <https://currentprotocols.onlinelibrary.wiley.com/doi/abs/10.1002/0471250953.bi1114s51>
  GOrilla                                                                           [@R26]                        <https://bmcbioinformatics.biomedcentral.com/articles/10.1186/1471-2105-10-48>
  REVIGO                                                                            [@R66]                        <https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0021800>
  GSEA                                                                              [@R65]                        <https://www.pnas.org/cgi/content/abstract/102/43/15545>
  MACS2                                                                             [@R71]                        <https://genomebiology.biomedcentral.com/articles/10.1186/gb-2008-9-9-r137>
  DiffBind                                                                          [@R59]                        <http://bioconductor.org/packages/release/bioc/vignettes/DiffBind/inst/doc/DiffBind.pdf>
  Other                                                                                                           
  Amicon 30kDa Ultrafiltraition spin columns                                        Millipore                     Cat\# UFC503096
  Amicon 3kDa Ultrafiltraition spin columns                                         Millipore                     Cat\# UFC500396
  Falcon Tube with Cell Strainer Cap                                                Fisher                        Cat\# 877123
  OneComp eBeads                                                                    eBioscience                   Cat\# 01-1111-41
  V-bottom 96 well plate                                                            Greiner                       Cat\# 651-180
  Maxisorp Immuno plates                                                            Nunc                          Cat\# 460984
  DNA LoBind Tubes                                                                  Eppendorf                     Cat\# 022431021
  96-well MultiScreen IP filter plates                                              Millipore                     Cat\# MSIPN4510

###### Highlights

-   High-dimensional profiling of CD4^+^ T cells in HIV-infected lymph nodes

-   A subset of CXCR5^−^ CD4^+^ T cells in lymph nodes are clonally related to T~FH~ cells

-   CXCR5^−^PD-1^+^ICOS^+^ CD4^+^ T cells exhibit T~FH~-like functional features

-   T~FH~-like CXCR5^−^ T cells contribute to circulating T cells with B cell help function
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